178 related articles for article (PubMed ID: 37923056)
101. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence.
Kirti A; Simnani FZ; Jena S; Lenka SS; Kalalpitiya C; Naser SS; Singh D; Choudhury A; Sahu RN; Yadav A; Sinha A; Nandi A; Panda PK; Kaushik NK; Suar M; Verma SK
Cancer Lett; 2024 Jul; 594():216990. PubMed ID: 38801886
[TBL] [Abstract][Full Text] [Related]
102. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.
Basar OY; Mohammed S; Qoronfleh MW; Acar A
Front Cell Dev Biol; 2024; 12():1369597. PubMed ID: 38813084
[TBL] [Abstract][Full Text] [Related]
103. Antibody-drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management.
Sarangi SC; Sopory P; Pattnaik SS; Reeta KH
Indian J Pharmacol; 2020; 52(5):402-413. PubMed ID: 33283772
[TBL] [Abstract][Full Text] [Related]
104. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Gupta R; Cristea M; Frankel P; Ruel C; Chen C; Wang Y; Morgan R; Leong L; Chow W; Koczywas M; Koehler S; Lim D; Luu T; Martel C; McNamara M; Somlo G; Twardowski P; Yen Y; Idorenyi A; Raechelle T; Carroll M; Chung V
Cancer Treat Res Commun; 2019; 21():100155. PubMed ID: 31279962
[TBL] [Abstract][Full Text] [Related]
105. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
106. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
107. Metronomic chemotherapy in ovarian cancer.
Garg V; Kumar L
Cancer Lett; 2023 Nov; 579():216469. PubMed ID: 37923056
[TBL] [Abstract][Full Text] [Related]
108. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
109. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
110. A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.
Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scibilia G; Scollo P; Gebbia V
J Oncol Pharm Pract; 2024 Jan; 30(1):173-181. PubMed ID: 38018146
[TBL] [Abstract][Full Text] [Related]
111. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
112.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
113.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
114.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
115.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
116.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
